Dapoflit G Tablet contains Dapagliflozin 10mg and Gliclazide 60mg, a dual-action anti-diabetic formulation designed to manage type 2 diabetes effectively. The combination helps achieve better glycemic control and reduces the risk of long-term complications.
The tablet works by enhancing urinary glucose excretion through Dapagliflozin and stimulating insulin secretion via Gliclazide, providing a synergistic approach for improved metabolic regulation. Its consistent efficacy and safety profile make it a preferred option for doctors treating complex diabetic patients.
For suppliers, Dapoflit G Tablet is a high-demand product in the anti-diabetic segment, offering excellent repeat prescription potential and reliable turnover. Its dual-action benefits make it attractive to endocrinologists, diabetologists, and general practitioners.
Including Dapoflit G in your product portfolio helps distributors strengthen their presence in the growing diabetes care market, enhance brand credibility among healthcare providers, and achieve better business growth with a clinically relevant and trusted formulation.
Possible side effects include hypoglycemia, dizziness, nausea, increased urination, urinary tract infections, and mild gastrointestinal discomfort. Rarely, severe hypoglycemia, dehydration, or allergic reactions may occur.
Dapoflit G Tablet is indicated for the treatment of type 2 diabetes mellitus, especially in patients inadequately controlled on diet, exercise, or monotherapy. It helps reduce blood glucose levels and improve glycemic control.
Use only under medical supervision. Not recommended in patients with type 1 diabetes, severe kidney or liver impairment, or known hypersensitivity to the components. Monitor blood sugar regularly and adjust diet and exercise accordingly.
Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.